Clinical Study to Evaluate Safety and Immunogenicity of Different Formulations of MF59-Adjuvanted Quadrivalent Subunit inactivated Cell-derived Influenze Vaccine (aQIVc) in Older Adults

| Funding period: 2021 - 2021

Completed

University of Melbourne Researchers